Hologic Inc.

HOLX | NASDAQ

Price Alert Chart Builder DCF Calculator

$76.01

$0 (0.00%)

Apr 7, 2026, 4:00 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.00%

(1D)

Rating

Updated: Apr 7, 2026

36.5

Fundamentals Weak

Market Sentiment Neutral

Moat Narrow

Full Analysis

Key Statistics

Market Data

Market Cap $16.97B

1D Range

76.01 76.01

52W Range

51.90 76.07

Valuation (TTM)

PE 31.67

PB 3.24

EV/EBITDA 16.89

Valuation (NTM)

Forward PE 15.58

Forward PEG 3.58

Price Target $79

Cash Flow

FCF Yield 5.9%

SBC Adj. FCF Yield 5.4%

SBC Impact -8.1%

Margins

Gross Margin 52.8%

Operating Margin 17.5%

FCF Margin 24.2%

Growth (CAGR)

Revenue 3Y | 5Y -2.6% | -1.9%

Dil EPS 3Y | 5Y -15.1% | -14.6%

FCF 3Y | 5Y -15.8% | -4.6%

Returns

ROA 5.9%

ROE 11.0%

ROIC 7.2%

Financial Health

Net Debt

$147.5M

Current Ratio 4.04

Interest Coverage 7.58

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, E...

Sector Healthcare

Industry Medical - Instruments & Supplies

Employees 7,063

IPO Date Feb 28, 1990

Website www.hologic.com

Fiscal Year October - September

Full Company Profile

Latest News

5 months ago · businesswire.com

New Evidence Backs Hologic's AI-Powered Mammography Technology for Detecting Challenging Cancers

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #WomensHealth--Research presented at the Society of Breast Imaging (SBI) Symposium backs Hologic AI-powered mammography technology for detecting challenging cancers.

6 months ago · businesswire.com

Hologic Chief Executive Officer Steve MacMillan to Retire Upon Close of Go-Private Transaction

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #holx--Hologic Chief Executive Officer Steve MacMillan to Retire Upon Close of Blackstone/TPG Acquisition.

6 months ago · zacks.com

Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It

Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

6 months ago · zacks.com

HOLX vs. ALGN: Which MedTech Stock Is the Better Investment Pick Now?

Align Technology's growth surges on record aligner demand and DSO expansion, while Hologic's near-complete buyout leaves little upside for investors.

6 months ago · zacks.com

Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.

6 months ago · zacks.com

Hologic's Women's Health Index Flags Alarming Gaps in STI Screening

HOLX's Global Women's Health Index shows STI testing stagnates at 10%, leaving nearly 2 billion women at risk despite gains in other screenings.

6 months ago · zacks.com

Should You Hold or Sell HOLX Stock as It Nears the End of Public Phase?

Hologic nears its $76 buyout price as Diagnostics faces headwinds, tariffs hurt, and the stock trades at a sector premium.

7 months ago · zacks.com

What Drives Hologic's GYN Surgical Strength in a Competitive Market?

HOLX expands its GYN Surgical reach with MyoSure, NovaSure and Gynesonics boost as the global women's health devices market grows and minimally invasive demand rises.

7 months ago · zacks.com

Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a Trending Stock

Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

7 months ago · zacks.com

Hologic's Diagnostics Strength in Focus: Is More Upside Ahead?

HOLX's Diagnostics unit faces COVID-19 test declines, but Panther Fusion expansion, new assays and AI-driven Genius system support long-term growth potential.